Melanotan I: Product & Research Information

Overview

Melanotan I, also known as afamelanotide or [Nle⁴, D-Phe⁷]-α-MSH, is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is associated with scientific research into melanocortin signaling, melanocyte activity, and biological pathways involved in skin pigmentation.

Melanotan I interacts with the melanocortin-1 receptor (MC1R), a receptor involved in regulating melanin production. Its pharmacological properties have been studied in connection with pigmentation and the body’s response to ultraviolet and visible light exposure.

Mechanism of Action

Melanotan I is an analogue of a naturally occurring peptide hormone involved in melanocortin signaling. Its activity at MC1R can stimulate pathways associated with the production of eumelanin, a type of melanin pigment.

Research into this pathway has contributed to the development of afamelanotide as a prescription medicine for a specific medical indication. However, the biological activity of a compound does not establish the safety, quality, or effectiveness of every product marketed under the name Melanotan I.

Research Background

Melanotan I and afamelanotide are discussed in scientific literature concerning melanocortin receptor activity and pigmentation biology. Afamelanotide is the active ingredient in SCENESSE, a prescription implant approved in the United States for increasing pain-free light exposure in adults with a history of phototoxic reactions associated with erythropoietic protoporphyria (EPP).

This specific approval applies to the authorized SCENESSE formulation and its labeled medical use. It should not be interpreted as approval of unapproved injectable or other online products marketed as Melanotan I, nor as evidence that the compound is an approved cosmetic tanning treatment.

Safety and Regulatory Considerations

Products marketed online as Melanotan I may differ in formulation, manufacturing standards, identity, concentration, and quality controls. The safety and effectiveness of an individual product should not be assumed from the compound name alone.

The approved afamelanotide medicine has documented risks, including nausea, skin hyperpigmentation, changes involving existing moles or freckles, and possible serious hypersensitivity reactions. Its prescribing information recommends regular skin examinations. These warnings are specific to the approved medicine and do not establish the safety profile of other formulations.

Melanotan I should not be presented as a proven or risk-free tanning solution. Anyone considering a product for personal use should consult a qualified healthcare professional and verify the product’s legal and regulatory status in their jurisdiction.

Product Information and Documentation

When evaluating a peptide or research-related product, relevant documentation may include the stated chemical identity, batch-specific analytical results, impurity information, and details about the testing laboratory. Such documents should be provided only when they genuinely exist and correspond to the actual batch.

A certificate of analysis, where available, does not by itself establish sterility, suitability for human use, clinical effectiveness, or regulatory approval.

Important Notice

This page provides general scientific and educational information about Melanotan I and afamelanotide. It is not medical advice and does not replace professional guidance or official prescribing information. Regulatory status varies by product formulation and jurisdiction. Always verify the status of the specific product rather than relying on the compound name alone.

Melanotan I safety

Melanotan I: Research & Safety Information | Peptika